GAUGING the GUIDELINES

Saturday, February 25th, 2017


Both the primary and secondary prevention of cardiovascular disease require a multidimensional approach, for which numerous guidelines exist in Canada. Through a unique patient-based format, clinical experts will discuss the latest advances and controversies in the various cardiovascular guidelines, with full delegate participation. Meant to be a practical and real-world experience, delegates will leave this symposium better equipped to effectively apply clinical guidelines in their daily practices.

Slides are available for CCRN members and those who have attended the program.

For more information with regards to becoming a CCRN member, please click HERE



Download Agenda »




Slides Available:

To receive access to the slides, please email Melinda Jones at mjones@ccrnmd.com

Debate: Pro- Guidelines dissemination should be free of pharma funding

David Alter

Not available

Debate: Con- Guidelines dissemination should be free of pharma funding

Robert Hegele

available

Atrial Fibrillation Update / Pro- Stable warfarin treated patients should be switched to a NOAC

Paul Dorian

available

Atrial Fibrillation: Con- Stable warfarin treated patients should be switched to a NOAC

Andrew Ha

available

Heart Failure Update / Pro- The Case for Sacubitril / Valsartan

Sean Virani

available

Con- The Case for Ivabridine

Peter Liu

available

Diabetes Update / Pro- Metformin should remain the first line agent

Amir Hanna

available

Con- Metformin should remain the first line agent

Ravi Retnakaran

available

Plenary Lecture- The CV Effects of Cancer and Cancer Therapies

Sean Virani

Not available

Plenary Lecture: Can you trust guidelines? Pearls for the clinician

Sanjay Kaul

available

Lipids Update/ Pro: The LDL target in high risk patients should be < 1.5

Milan Gupta

available

Con: The LDL target in high risk patients should be < 1.5

Robert Hegele

available

Hypertension Update/ Pro: SBP <120 should be the target for most patients with hypertension

Sheldon Tobe

available

Con: SBP <120 should be the target for most patients with hypertension

James Stone

available